SCHEDULE 13G/A: BlackRock Maintains Significant 7.5% Stake in Guardant Health, Files Updated Beneficial Ownership Report

BlackRock, Inc. has filed an updated Schedule 13G, reaffirming its substantial passive ownership of 7.5% of Guardant Health, Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 9,288,801 shares of Guardant Health, Inc. common stock.
• This ownership represents 7.5% of the total outstanding common stock of Guardant Health, Inc.
• BlackRock holds sole voting power over 9,145,510 shares and sole dispositive power over 9,288,801 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of Guardant Health.
• The filing is an Amendment No. 2 to a previous Schedule 13G.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Investment Management (UK) Limited, are identified as entities that may beneficially own shares, with some potentially owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a major institutional investor like BlackRock maintaining a significant stake (7.5%) in Guardant Health suggests continued confidence. There are no negative elements or adverse disclosures within the filing itself.

Positives

• BlackRock, a major institutional investor, maintaining a significant 7.5% stake in Guardant Health could be interpreted as a sign of continued confidence in the company's long-term prospects.
• The passive nature of the investment, as certified by BlackRock, suggests stability in the ownership structure without immediate intent for corporate control changes.

Future Outlook

The document does not provide any forward-looking statements or guidance from Guardant Health, Inc. as it is a beneficial ownership report filed by BlackRock, Inc.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from BlackRock, Inc.)

Industry Context

This filing reflects the ongoing investment activities of large asset managers like BlackRock within the healthcare and biotechnology sectors, specifically in companies like Guardant Health, which operates in precision oncology. Such filings are standard disclosures for significant passive stakes, indicating continued institutional interest in the sector.

Stakeholder Impact

• Shareholders: The continued significant ownership by BlackRock may provide a level of stability and confidence to other shareholders, signaling a major institutional investor's long-term interest.
• Potential Investors: The disclosure of a large institutional stake can influence the perception of Guardant Health's investment attractiveness.

Key Dates

Keywords

Guardant Health, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing